Posted by Michael Wonder on 29 Dec 2025
Praxis Precision Medicines announces the FDA has granted breakthrough therapy designation for ulixacaltamide hydrochloride in essential tremor
29 December 2025 - The breakthrough therapy designation was granted based on the positive top-line results from the Essential3 Phase 3 program in essential tremor.
Praxis Precision Medicines today announced that the US FDA has granted breakthrough therapy designation for ulixacaltamide, a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of patients with essential tremor.
